Experimental Compounds Show Promise in Reducing Brain Inflammation Linked to Alzheimer's
Similar Articles
Researchers Identify New Enzyme Target That Reduces Alzheimer's Plaques in Lab Studies
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
Research Identifies Protein Target That Improves Memory in Alzheimer's Mouse Model
Anti-Amyloid Drugs Show Limited Benefit for Early Alzheimer's, Carry Side Effects
Researchers at the University of Southern California (USC) have identified experimental compounds that could reduce brain inflammation associated with Alzheimer's disease. The compounds target an enzyme linked to the disease's strongest known genetic risk factor and have shown potency in early cell and animal models. The findings, published in the journal npj Drug Discovery, represent a step toward a potential new therapeutic approach.
Facts First
- Experimental compounds target the cPLA2 enzyme, which is linked to brain inflammation in Alzheimer's disease.
- Elevated cPLA2 activity is associated with the APOE4 gene, the strongest known genetic risk factor for Alzheimer's.
- A leading compound candidate reduced harmful cPLA2 activation in human brain cells under Alzheimer's-related stress.
- In mouse studies, the compound crossed the blood-brain barrier and influenced relevant neuroinflammatory pathways.
- The research team used large-scale computational screening to evaluate billions of molecules for potential treatments.
What Happened
Researchers at the University of Southern California (USC) identified experimental compounds that could reduce brain inflammation associated with Alzheimer's disease. The research focuses on an enzyme called calcium-dependent phospholipase A2 (cPLA2), which plays a role in brain inflammation. The USC team linked elevated cPLA2 activity to Alzheimer's risk in people carrying the APOE4 gene, the strongest known genetic risk factor for the disease. Using large-scale computational screening methods developed by Vsevolod 'Seva' Katritch, the team evaluated billions of possible molecules. One cPLA2 inhibitor was identified as the leading candidate after reducing harmful cPLA2 activation in human brain cells exposed to Alzheimer's-related stress conditions. In mouse studies led by pharmacologist Stan Louie, the compound crossed the blood-brain barrier and influenced neuroinflammatory pathways linked to Alzheimer's disease. Senior author Hussein Yassine stated that the identified compounds act selectively on cPLA2 with minimal effects on related enzymes important for normal cellular function.
Why this Matters to You
If you or a family member carries the APOE4 gene, this research may eventually lead to new preventative or therapeutic options targeting a specific inflammatory pathway linked to your genetic risk. For the broader population, the discovery of a compound that can selectively target brain inflammation and cross the protective blood-brain barrier represents a significant technical hurdle that has been overcome in early testing. This could pave the way for a new class of drugs that might slow disease progression. The selective action of the compounds, as noted by the researchers, suggests they could be designed to minimize side effects by sparing other important cellular functions, which is a common challenge in drug development.
What's Next
The findings, published in the Nature journal npj Drug Discovery, will likely lead to further preclinical testing to refine the leading compound candidate and assess its safety and efficacy in more complex models. The researchers involved... are founders of PeBRx, a company developing cPLA2 inhibitors, indicating a path toward commercial drug development. Further research may also explore whether these compounds are effective in people who carry the APOE4 gene, as this study established a strong link between the gene and the cPLA2 inflammation pathway.